TGAL5 Antibody

What is TGR5/GPBAR1 and why is it significant in research?

TGR5 (also known as GPBAR1) is the first identified bile acid-sensing G-protein coupled receptor that has emerged as a potential therapeutic target for metabolic disorders. The receptor is widely expressed in various tissues including liver, intestine, and both central and enteric nervous systems. Research indicates that TGR5 activation leads to anti-inflammatory effects and influences energy homeostasis and glucose metabolism, suggesting a role in the pathogenesis of obesity and diabetes . These physiological functions make TGR5 a critical research target for understanding metabolic regulation pathways and developing potential therapeutics for metabolic disorders.

Which cell types are most appropriate for studying TGR5/GPBAR1 expression?

HEK293 human embryonic kidney cell lines transfected with human TGR5/GPBAR1 have been successfully used as positive controls in research applications . Before designing experiments, it's essential to perform a thorough background check on target expression in different cell lines. The Human Protein Atlas and literature searches via PubMed, Google Scholar, or Scopus can provide valuable information about expression patterns in various cell types. For endogenous expression studies, tissues such as liver, intestine, and nervous system components where TGR5 is naturally expressed would be appropriate. Always include a positive control cell line with known TGR5 expression when studying experimental cell lines .

What are the optimal storage conditions for TGR5/GPBAR1 antibodies?

For maximum stability and activity retention, TGR5/GPBAR1 antibodies should be stored at -20 to -70°C for long-term storage (up to 12 months from the date of receipt). After reconstitution, the antibody can be stored at 2 to 8°C under sterile conditions for approximately one month, or at -20 to -70°C for up to six months . It's crucial to use a manual defrost freezer and avoid repeated freeze-thaw cycles as these can significantly degrade antibody quality and performance. For working solutions, aliquoting is recommended to minimize freeze-thaw cycles and maintain consistent antibody performance across experiments.

How should flow cytometry experiments be designed for optimal TGR5/GPBAR1 detection?

When designing flow cytometry experiments for TGR5/GPBAR1 detection, follow these methodological steps:

• Begin with careful cell preparation, ensuring >90% viability to avoid false positive staining from dead cells.

• Use an appropriate cell concentration (10^5 to 10^6 cells) to prevent clogging of the flow cell.

• For cell surface detection of TGR5, cells can often be used unfixed, while intracellular detection requires proper fixation and permeabilization.

• Include essential controls:

  • Unstained cells to account for autofluorescence

  • Negative cell populations not expressing TGR5

  • Isotype controls (same antibody class but with no specificity for your target)

  • Secondary antibody controls when using indirect staining methods

• Use appropriate blocking agents (10% normal serum from the same host species as the labeled secondary antibody) to reduce non-specific binding.

• Perform all protocol steps on ice and consider using PBS with 0.1% sodium azide to prevent internalization of membrane antigens .

TGR5/GPBAR1 detection has been successfully demonstrated in HEK293 cells transfected with TGR5/GPBAR1 using monoclonal antibodies followed by fluorophore-conjugated secondary antibodies .

What are the recommended protocols for immunoprecipitation studies involving TGR5/GPBAR1?

For immunoprecipitation of TGR5/GPBAR1, the following methodological approach has proven effective:

• Prepare cell lysates in an appropriate buffer containing protease inhibitors (e.g., 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 20 mM p-nitrophenylphosphate, 200 μM sodium orthovanadate, 100 μM phenylmethylsulfonyl fluoride, and protease inhibitors including leupeptin, pepstatin A, and aprotinin).

• Mix cell lysate supernatants with TGR5 antibody-IP matrix complex and incubate at 4°C on a rotator for approximately 5 hours.

• Recover immunoadsorbents by centrifugation at 700×g for 5 minutes.

• Wash the immunoprecipitates three times with cell lysis buffer.

• Resuspend in SDS loading buffer and heat at 100°C for 5 minutes before SDS-PAGE separation .

This protocol has been used successfully to investigate G protein coupling with TGR5 receptors, revealing associations with Gαq and Gαi-3 proteins .

How can researchers minimize heterophile antibody interference in TGR5/GPBAR1 immunoassays?

To minimize heterophile antibody interference in TGR5/GPBAR1 immunoassays, implement these methodological approaches:

• Pre-test samples for interfering antibodies that might cross-react with assay components.

• Incorporate commercial heterophile antibody blocking reagents containing animal-derived proteins (particularly murine proteins) in a buffered salt solution.

• Validate results through alternative detection platforms when possible.

• Perform serial dilutions of samples to identify potential interference (non-linear dilution patterns indicate potential interference).

• Include negative controls and isotype-matched antibody controls in your experimental design .

Although these recommendations are derived from thyroglobulin immunoassay practices, the same principles apply to minimizing interference in TGR5/GPBAR1 detection systems. Heterophile antibodies are a common source of false-positive or false-negative results in immunoassays and should be systematically addressed in research protocols.

How does the Y111 residue affect TGR5 oligomerization, and what are the implications for antibody binding studies?

The Y111 residue, located in transmembrane helix 3 within the highly conserved ERY motif of TGR5, plays a critical role in the formation of higher-order oligomers. Research using Multiparameter Image Fluorescence Spectroscopy (MFIS) for quantitative FRET analysis has revealed that:

• Wild-type TGR5 naturally forms higher-order oligomers (likely tetramers).

• The Y111A mutation disrupts this process, resulting primarily in dimeric structures.

• The higher-order oligomers typically form a linear arrangement with interaction sites involving transmembrane helix 1, helix 8, and transmembrane helix 5 .

For antibody binding studies, these structural characteristics have significant implications:

• Epitope accessibility may differ between monomeric, dimeric, and tetrameric forms of TGR5

• Antibodies targeting regions involved in oligomer interfaces might show different binding affinities depending on the oligomerization state

• Mutations affecting the oligomerization pattern (such as Y111A) could alter antibody recognition sites

Researchers should consider these oligomerization properties when selecting antibodies for different applications and when interpreting binding data, particularly when working with mutant variants of TGR5 .

What G protein coupling patterns should be considered when studying TGR5/GPBAR1 signaling pathways?

When investigating TGR5/GPBAR1 signaling pathways, researchers should account for the following G protein coupling patterns:

• TGR5 receptors have been demonstrated to couple with both Gαq and Gαi-3 proteins through co-immunoprecipitation studies.

• Of these interactions, only Gαq has been shown to mediate certain downstream effects, such as TDCA-induced increases in NOX5-S expression, H₂O₂ production, and thymidine incorporation in cellular models .

For comprehensive signaling studies, researchers should:

• Test for interactions with multiple G protein subtypes (Gαq, Gαs, Gα13, Gαi-3, Gαi-1-2)

• Use specific inhibitors of G protein subtypes to dissect signaling pathways

• Consider cell-type specific variations in G protein coupling patterns

• Verify findings with knockdown/overexpression approaches to confirm specific G protein involvement

Understanding these coupling patterns is essential for accurately characterizing TGR5-mediated signaling events and for developing potential therapeutic approaches targeting specific downstream pathways .

What are the methodological considerations for studying TGR5/GPBAR1 expression in different tissue types?

When investigating TGR5/GPBAR1 expression across different tissue types, several methodological considerations should be addressed:

• Tissue-specific expression patterns: Research has demonstrated that TGR5 mRNA and protein levels vary significantly between tissues, with notably higher expression in certain pathological conditions. For example, studies have shown significantly higher TGR5 levels in OA tissues compared to normal esophageal mucosa or Barrett's mucosa .

• Antibody validation: Before proceeding with tissue expression studies, validate antibody specificity using:

  • Positive control tissues/cells with known TGR5 expression

  • Negative control tissues where TGR5 is not expressed

  • Western blot analysis to confirm antibody specificity (typically used at 1:1000 dilution)

• Complementary detection methods: Employ multiple techniques to confirm expression findings:

  • qRT-PCR for mRNA expression

  • Western blotting for protein levels

  • Immunohistochemistry/immunofluorescence for spatial distribution

  • Flow cytometry for quantitative cellular analysis

• Fixation and antigen retrieval: Different tissues may require optimized protocols for preserving TGR5 antigenicity while maintaining tissue architecture. Test multiple fixation methods (formalin, paraformaldehyde, methanol) and antigen retrieval techniques to determine optimal conditions for each tissue type.

• Controls for tissue autofluorescence: Particularly in tissues with high autofluorescence (like liver), implement appropriate controls and quenching techniques to distinguish true antibody binding from background signals .

How can researchers validate TGR5/GPBAR1 antibody specificity for their applications?

To rigorously validate TGR5/GPBAR1 antibody specificity, implement the following methodological approach:

• Expression systems validation:

  • Test the antibody on cells with confirmed TGR5 expression (e.g., HEK293 cells transfected with human TGR5/GPBAR1)

  • Compare with negative controls using the same cell line transfected with irrelevant proteins

  • Utilize siRNA or CRISPR knockout models to confirm specificity

• Multiple detection techniques:

  • Confirm specificity across different applications (Western blot, flow cytometry, immunoprecipitation)

  • For each technique, use appropriate positive and negative controls

  • Consider epitope accessibility differences between applications

• Peptide competition assays:

  • Pre-incubate the antibody with excess purified TGR5 peptide

  • A true specific antibody will show significantly reduced or eliminated binding

• Cross-reactivity assessment:

  • Test on tissues/cells from different species if the antibody is claimed to be cross-reactive

  • Evaluate potential cross-reactivity with structurally related GPCRs

• Isotype controls:

  • Use isotype-matched control antibodies of the same class as the TGR5 antibody but with no known specificity for TGR5

Thorough validation ensures experimental results accurately reflect TGR5 biology rather than non-specific antibody interactions or technical artifacts.

What factors contribute to inconsistent Western blot results when detecting TGR5/GPBAR1?

When troubleshooting inconsistent Western blot results for TGR5/GPBAR1 detection, consider these methodological factors:

• Sample preparation:

  • TGR5 is a membrane protein; insufficient membrane solubilization can reduce detection

  • Use appropriate lysis buffers containing Triton X or other suitable detergents

  • Ensure complete protease inhibition to prevent degradation

  • Consider native vs. denaturing/reducing conditions based on antibody epitope requirements

• Protein loading and transfer:

  • Membrane proteins may require optimization of transfer conditions (time, voltage, buffer composition)

  • Confirm successful transfer using stains like Ponceau S

  • Ensure equal protein loading by normalizing to appropriate housekeeping proteins

• Antibody conditions:

  • Optimize primary antibody dilution (typically 1:1000 for TGR5)

  • Evaluate different blocking agents to reduce background

  • Test various incubation temperatures and times

• TGR5 oligomerization state:

  • Different oligomeric forms (monomers, dimers, tetramers) may appear at different molecular weights

  • The Y111 residue affects oligomerization patterns, potentially altering band patterns

  • Consider variations in sample preparation that might disrupt oligomers

• Post-translational modifications:

  • TGR5 may undergo glycosylation or other modifications that affect apparent molecular weight

  • Sample treatments affecting these modifications could result in band shifts

Systematic evaluation of these factors should help identify the source of inconsistency and establish a reliable detection protocol.

How should researchers interpret flow cytometry data for TGR5/GPBAR1 expression in heterogeneous cell populations?

When interpreting flow cytometry data for TGR5/GPBAR1 expression in heterogeneous cell populations, follow these methodological guidelines:

• Gating strategy development:

  • Begin with forward/side scatter to identify viable cells and exclude debris

  • Use viability dyes to eliminate dead cells that may bind antibodies non-specifically

  • Employ additional markers to identify specific cell subpopulations of interest

• Control-based interpretation:

  • Set quadrant markers based on appropriate isotype controls (e.g., Mouse IgG 2B Isotype Control)

  • Use unstained samples to account for autofluorescence in each cell population

  • Include FMO (fluorescence minus one) controls when using multiple markers

• Quantitative analysis approaches:

  • Report both percentage of positive cells and mean/median fluorescence intensity

  • For heterogeneous expression, consider histogram overlays or contour plots

  • Use statistical methods appropriate for non-parametric distributions when necessary

• Validation with complementary techniques:

  • Confirm flow cytometry findings with immunofluorescence microscopy

  • Use cell sorting followed by Western blot or qPCR to verify expression in specific populations

  • Consider single-cell approaches for highly heterogeneous populations

• Data presentation standards:

  • Present raw data alongside analyzed results

  • Include all controls in supplementary materials

  • Clearly indicate gating hierarchies and thresholds

This systematic approach allows for accurate quantification of TGR5/GPBAR1 expression across different cell types within complex populations, providing insight into differential expression patterns that may have functional significance .

How can structural insights into TGR5 oligomerization inform antibody development strategies?

The emerging understanding of TGR5 oligomerization patterns offers several strategic directions for antibody development:

• Epitope-specific targeting strategies:

  • Research has revealed that TGR5 forms higher-order oligomers (likely tetramers) with specific interaction sites involving transmembrane helix 1, helix 8, and transmembrane helix 5

  • The Y111 residue in transmembrane helix 3 plays a critical role in this oligomerization process

  • Developing antibodies specifically targeting accessible epitopes in different oligomeric states could allow selective detection of monomeric, dimeric, or tetrameric forms

• Conformational antibodies:

  • Antibodies designed to recognize interface regions could serve as tools to study the dynamics of TGR5 oligomerization in different cellular contexts

  • Such antibodies might also distinguish between active and inactive receptor conformations

• Functional modulation:

  • Antibodies targeting specific domains involved in G protein coupling (Gαq and Gαi-3 interaction sites) could serve as experimental tools to modulate TGR5 signaling selectively

  • This approach could help dissect the relative contributions of different signaling pathways to physiological outcomes

• Therapeutic applications:

  • Understanding the functional significance of different oligomeric states could inform therapeutic antibody development

  • Antibodies that stabilize or disrupt specific oligomeric forms might provide novel approaches to modulating TGR5 activity in metabolic disorders

These strategies represent high-value directions for advancing both basic research tools and potential therapeutic approaches targeting TGR5.

What methodological approaches can overcome challenges in detecting low-abundance TGR5/GPBAR1 in primary tissues?

Detecting low-abundance TGR5/GPBAR1 in primary tissues presents significant technical challenges that can be addressed through these advanced methodological approaches:

• Signal amplification techniques:

  • Tyramide signal amplification (TSA) for immunohistochemistry/immunofluorescence

  • Proximity ligation assay (PLA) for detecting protein-protein interactions with single-molecule sensitivity

  • Quantum dot-conjugated secondary antibodies for improved signal-to-noise ratio

• Enrichment strategies:

  • Membrane fraction isolation prior to analysis

  • Laser capture microdissection to isolate specific cell populations with higher TGR5 expression

  • Immunoprecipitation followed by highly sensitive detection methods

• Ultrasensitive detection platforms:

  • Digital ELISA/Single molecule array (Simoa) technology

  • Mass cytometry (CyTOF) for multiparameter analysis with minimal spectral overlap

  • Super-resolution microscopy techniques (STED, PALM, STORM) for improved spatial resolution

• Genetic reporter systems:

  • CRISPR knock-in of fluorescent or luminescent tags to endogenous TGR5

  • Amplification-based detection of TGR5 mRNA using RNAscope or similar technologies

  • Single-cell transcriptomics to identify cells expressing TGR5 mRNA

• Data analysis enhancement:

  • Machine learning algorithms for signal extraction from noisy backgrounds

  • Deconvolution techniques for improved image analysis

  • Integrative multi-omics approaches combining proteomics, transcriptomics, and functional data

These advanced approaches can significantly improve detection sensitivity while maintaining specificity, enabling accurate assessment of TGR5/GPBAR1 expression in tissues where conventional methods may fall short.

How might TGR5/GPBAR1 post-translational modifications affect antibody recognition and experimental outcomes?

Post-translational modifications (PTMs) of TGR5/GPBAR1 can significantly impact antibody recognition and experimental results through several mechanisms:

• Epitope masking or alteration:

  • Phosphorylation, glycosylation, ubiquitination, or other PTMs may directly modify antibody recognition sites

  • PTMs near but not within epitopes can affect three-dimensional structure and accessibility

  • Some antibodies may preferentially recognize specific modified or unmodified forms

• Oligomerization state changes:

  • PTMs can influence TGR5's ability to form higher-order oligomers

  • As TGR5 naturally forms tetramers through specific interaction interfaces , PTMs affecting these interfaces may alter oligomerization patterns

  • Antibodies targeting regions involved in oligomer formation may show differential binding based on oligomerization state

• Subcellular localization effects:

  • PTMs often regulate membrane protein trafficking between cellular compartments

  • Antibodies designed for surface detection may show variable results depending on the proportion of internalized receptor

  • Fixed/permeabilized vs. non-permeabilized detection protocols may yield different results based on receptor localization

• Methodological considerations:

  • Sample preparation protocols may preserve or disrupt certain PTMs

  • Phosphatase or glycosidase treatments can be used experimentally to determine PTM effects on antibody binding

  • Using multiple antibodies targeting different epitopes can help create a more complete picture of TGR5 biology

• Functional correlation:

  • Developing modification-specific antibodies can help correlate specific PTMs with receptor functional states

  • These tools can provide insights into how signaling events regulate TGR5 activity

Researchers should carefully consider the potential impact of PTMs when selecting antibodies, designing experiments, and interpreting results involving TGR5/GPBAR1 detection and functional studies.